Jeffrey Bornstein

Company: Eledon Pharmaceuticals Inc.
Job title: Chief Medical Officer
Seminars:
– Evaluating a Next Generation Anti-CD40L Antibody as a Therapy for Patients with ALS 11:30 am
The rationale for targeting CD40L in patients with ALS Results of a pilot study targeting CD40L in patients with ALS Looking to the future with targeting CD40L in patients with ALSRead more
day: Day Two AM